-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Endovascular therapy (EVT) has revolutionized the treatment of acute ischemic stroke caused by large vessel occlusion
Despite high recanalization rates, approximately half of treated patients did not achieve functional independence after EVT
Observational studies in hypertension have repeatedly demonstrated an association between hypertension and poor outcomes after successful reperfusion, a finding that is also supported by preclinical studies
This is a post hoc analysis of the BP-TARGET multicenter trial
RESULTS: A total of 267 patients (130 in the intensive treatment group) were included
After adjusting for potential confounders including baseline SBP, both ΔSBP15-60M and ΔSBP6-24H reductions were significantly associated with lower odds of adverse outcome (OR = 5 mmHg SBP reduction, respectively, 0.
A reduction in ΔSBP15-60M was significantly associated with a lower chance of any intravascular hemorrhage (OR = 5 mmHg SBP reduction, 0.
Taken together, ΔSBP was linearly associated with adverse outcomes after successful reperfusion, with the lesser the decrease in SBP from baseline, the higher the risk of adverse outcomes
Taken together, ΔSBP was linearly associated with adverse outcomes after successful reperfusion, with the lesser the decrease in SBP from baseline, the higher the risk of adverse outcomes
references:
Magnitude of Blood Pressure Change After Endovascular Therapy and Outcomes: Insight From the BP-TARGET Trial.
Magnitude of Blood Pressure Change After Endovascular Therapy and Outcomes: Insight From the BP-TARGET Trial.
https://doi.
org/10.
1161/STROKEAHA.
121.
036701
Leave a comment here